MannKind Corporation (MNKD) |
|
4.07 -0.09 (-2.16%)
|
03-17 16:00 |
|
Open: |
4.11 |
Pre. Close: |
4.16 |
|
High:
|
4.145 |
Low:
|
3.99 |
|
Volume:
|
6,175,763 |
Market Cap:
|
1,074(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:47:41 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 5.91 One year: 6.69 |
| Support: |
Support1: 3.99 Support2: 3.31 |
| Resistance: |
Resistance1: 5.06 Resistance2: 5.73 |
| Pivot: |
4.63  |
| Moving Average: |
MA(5): 4.19 MA(20): 4.81
MA(100): 4.68  MA(250): 4.07 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 5.9 %D(3): 4.9 |
| RSI: |
RSI(14): 27.1 |
| 52-week: |
High: 5.73 Low: 2.6 |
| Average Vol(K): |
3-Month: 3,515 (K) 10-Days: 3,731 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MNKD ] has closed above bottom band by 13.2%. Bollinger Bands are 81.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.16 - 4.18 |
4.18 - 4.2 |
|
Low:
|
3.92 - 3.95 |
3.95 - 3.98 |
|
Close:
|
4.02 - 4.07 |
4.07 - 4.11 |
|
Company Description |
|
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. |
Headline News |
Tue, 14 Mar 2023
MannKind (MNKD) Shares Cross Below 200 DMA - Nasdaq
Mon, 13 Mar 2023
MannKind Becomes Oversold (MNKD) - Nasdaq
Thu, 09 Mar 2023
After Hours Most Active for Mar 9, 2023 : SWN, GRAB, ATCO, BAC ... - Nasdaq
Tue, 07 Mar 2023
MannKind Corporation to Participate in Oppenheimer 33rd Annual ... - StreetInsider.com
Mon, 06 Mar 2023
MannKind Corp (MNKD) has fallen -10.41% in a Week, Should You Hold? - InvestorsObserver
Mon, 27 Feb 2023
SVB Leerink Comments on MannKind Co.'s Q1 2023 Earnings ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
263 (M) |
| Shares Float |
260 (M) |
|
% Held by Insiders
|
6.1 (%) |
|
% Held by Institutions
|
48.9 (%) |
|
Shares Short
|
34,320 (K) |
|
Shares Short P.Month
|
29,270 (K) |
Stock Financials |
|
EPS
|
-0.26 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.92 |
|
EPS Est Next Year
|
-0.76 |
|
Book Value (p.s.)
|
-0.75 |
|
Profit Margin (%)
|
-128 |
|
Operating Margin (%)
|
-111.7 |
|
Return on Assets (ttm)
|
-20 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
47.7 |
|
Gross Profit (p.s.)
|
0.13 |
|
Sales Per Share
|
0.28 |
|
EBITDA (p.s.)
|
-0.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-91 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-15.84 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
-5.43 |
|
Price to Sales
|
14.05 |
|
Price to Cash Flow
|
-11.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-03-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
